Evidence of intestinal inflammation in patients with cystic fibrosis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 51, Issue 3, 2010, Pages 304-308

  Werlin, Steven L ^a   Benuri Silbiger, Ishay ^b   Kerem, Eitan ^c   Adler, Sam N ^d   Goldin, Eran ^b   Zimmerman, Joseph ^b   Malka, Netta ^b,c   Cohen, Limor ^b,c   Armoni, Shoshana ^c   Yatzkan Israelit, Yardena ^d   Bergwerk, Ari ^a   Aviram, Micha ^c   Bentur, Lea ^e   Mussaffi, Huda ^f   Bjarnasson, Ingvar ^g   Wilschanski, Michael ^b,c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d BIKUR CHOLIM HOSPITAL   (Israel)

^e RAMBAM MEDICAL CENTER   (Israel)

^f SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

calprotectin; capsule endoscopy; cystic fibrosis

Indexed keywords

CALGRANULIN;

ADOLESCENT; ADULT; ARTICLE; CAPSULE ENDOSCOPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; EDEMA; ENTERITIS; ERYTHEMA; FECES ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; INTESTINE MUCOSA; INTESTINE ULCER; MALE; PANCREAS INSUFFICIENCY; PRIORITY JOURNAL; SCHOOL CHILD; SMALL INTESTINE;

ADOLESCENT; ADULT; CAPSULE ENDOSCOPY; CHILD; CYSTIC FIBROSIS; EDEMA; ERYTHEMA; EXOCRINE PANCREATIC INSUFFICIENCY; FECES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INCIDENCE; INFLAMMATION; INTESTINAL MUCOSA; INTESTINE, SMALL; LEUKOCYTE L1 ANTIGEN COMPLEX; LUNG; MALE; MIDDLE AGED; MUCOSITIS; ULCER; YOUNG ADULT;

EID: 77956439080     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181d1b013     Document Type: Article

References (31)

1. United Kingdom CF Database Cystic Fibrosis Trust http://www. cysticfibrosis. org.uk.
2. Borowitz D, Durie PR, Clarke LL, et al. Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr Gastroenterol Nutr 2005; 41:273-85.
3. Negila JP, FitzSimmons SC, Maisonneuve P, et al. Risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med 1995;332:494-9.
4. Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW 3rd, Lowenfels AB. Cancer risk in non transplanted and transplanted cystic fibrosis patient: a 10 year study. J Natl Cancer Inst 2003;95:381-7.
5. Norkina O, Kaur S, Zeimer D, De Lisle RC. Inflammation of cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2004;286:G1032-41.
6. Freye HB, Kurtz S, Spock A, Capp MP. Light and electron microscopic examination of the small bowel of children with cystic fibrosis. J Pediatr 1964;64:575-9.
7. Thomadis TS, Arey JB. The intestinal lesions in cystic fibrosis of the pancreas. J Pediatr 1963;63:16-21.
8. Eggermont E. The role of the small intestine in cystic fibrosis patients. Acta Paediatr Scand Suppl 1985;317:16-21.
9. Raia V, Maiuri L, de Ritis G, et al. Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatr Res 2000;47:344-50.
10. Hallberg K, Grzegorczyk A, Larson G, Strandvik B. Intestinal permeability in cystic fibrosis in relation to genotype. J Pediatr Gastroenterol Nutr 1997;25:290-5.
11. Van Elburg RM, Uil JJ, van Aalderen WM, Mulder CJ, Heymans HS. Intestinal permeability in exocrine pancreatic insufficiency due to cystic fibrosis or chronic pancreatitis. Pediatr Res 1996;39:985-91.
12. Escobar H, Perdomo M, Vasconez F, et al. Intestinal permeability to 51Cr-EDTA and orocecal transit time in cystic fibrosis. J Pediatr Gastroenterol Nutr 1992;14:204-7.
13. Leclercq-Foucart J, Forget PP, Van Cutsem JL. Lactulose-rhamnose Intestinal permeability in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 1987;6:66-70.
14. Leclercq-Foucart J, Forget P, Sodoyez-Goffaux F, Zappitelli A. Intestinal permeability to [51Cr]EDTA in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 1986;5:384-7.
15. Bjarnason I, Takeuchi K, Bjarnason A, et al. The G.U.T. of gut. Scand J Gastroenterol 2004;39:807-15.
16. Smyth RL, Croft NM, O'Hea U, et al. Intestinal inflammation in cystic fibrosis. Arch Dis Child 2000;82:394-9.
17. Croft NM, Marshall TG, Ferguson A. Gut inflammation in children with cystic fibrosis on high dose enzyme supplements. Lancet 1995; 346:1265-7.
18. Croft NM, Marshall TG, Ferguson A. Direct assessment of gastrointestinal inflammation and mucosal immunity in children with cystic fibrosis. Postgrad Med J 1996;72 (Suppl 2):S32-6.
19. Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008;40:547-53.
20. Sidhue R, McAlindon ME, Sanders DS, Thomson M. Capsule endoscopy in the evaluation of gastrointestinal disease. Curr Opin Pediatr 2007;29:586-90.
21. Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007;5:1040-5.
22. Johne B, Kronborg O, Ton H, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001;36:291-6.
23. Bensalem N, Ventura AP, Vallee B, et al. Down-regulation of the antiinflammatory protein Annexin-1 in cystic fibrosis knock-out mice and patients. Mol Cell Proteomics 2005;4:1591-601. (Pubitemid 41555482)
24. Kornbluth A, Colombel JF, Leighton JA, Loftus E. ICCE consensus for inflammatory bowel disease. Endoscopy 2005;37:1051-4.
25. Gralnek IM, Defranchis R, Seidman E, et al. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther 2008;27:146-54.
26. Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole and placebo. Clin Gastroenterol Hepatol 2005;3:133-41.
27. Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprophen plus omeprazole as assessed by video capsule endoscopy. Aliment Pharmacol Therap 2007;25:1211-22.
28. FitzSimmons SC, Burkhart GA, Norowitch D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997;336:1283-9.
29. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123:450-60.
30. Bruzzese E, Raia V, Gaudiello G, et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther 2004;20:813-9.
31. Bruzzese E, Raia V, Spagnuolo MI, et al. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin Nutr 2007;26:322-8.